Impetigo

22 registered clinical trials studyying Impetigo — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Perspectives on Antibiotics and Tracking Symptoms in Children NCT07093749	Murdoch Childrens Research Institute	N/A
Completed	Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin NCT07428915	AI Labs Group S.L	—
Completed	Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care NCT05226260	Nationwide Children's Hospital	N/A
Completed	Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo NCT03429595	UNION therapeutics	Phase 2
Completed	Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminth NCT03177993	Washington University School of Medicine	N/A
Completed	Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo NCT02902822	Centro Studi Gised	N/A
Completed	Azithromycin - Ivermectin Mass Drug Administration for Skin Disease NCT02775617	London School of Hygiene and Tropical Medicine	Phase 4
Completed	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo NCT02090764	Ferrer Internacional S.A.	Phase 3
Completed	Safety and Efficacy of Mupirocin Gel in Children With Impetigo NCT04287777	Reig Jofre Group	Phase 3
Unknown	The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointmen NCT01943136	Philippine Dermatological Society	Phase 1
Completed	Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo NCT01670032	NovaBay Pharmaceuticals, Inc.	Phase 2 / Phase 3
Unknown	Citriodiol® and Impetigo NCT01611909	Royal North Shore Hospital	Phase 2 / Phase 3
Completed	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo NCT01397461	Ferrer Internacional S.A.	Phase 3
Completed	Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients NCT01171326	Vyne Therapeutics Inc.	Phase 2
Completed	Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection NCT01126268	The University of Texas Health Science Center, Houston	Phase 4
Completed	Safety and Efficacy of Topical NVC-422 Gel in Impetigo NCT01367314	NovaBay Pharmaceuticals, Inc.	Phase 2
Completed	The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impeti NCT00758862	LEO Pharma	Phase 2
Completed	EU PV for Retapamulin-Prescribing NCT01153828	GlaxoSmithKline	—
Completed	Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions ( NCT00626795	LEO Pharma	Phase 2
Completed	Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment NCT00133848	GlaxoSmithKline	Phase 3
Completed	Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territo NCT00884728	Menzies School of Health Research	—
Terminated	Fucidin® Cream in the Treatment of Impetigo NCT00986856	LEO Pharma	Phase 4